Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +34.74%
#2 Cortex Cortex +32.63%
#3 DexNet DexNet +23.20%
#4 wojak wojak +21.48%
#5 Akedo Akedo +20.54%
#6 Pons Pons +18.91%
#7 SODAX SODAX +17.42%
#8 APEX APEX +13.93%
#9 ETHGas ETHGas +13.11%
#10 OpenEden OpenEden +12.21%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Ascentage Pharma Group International Ascentage Pharma Group International

Ascentage Pharma Group International

AAPG
Rang în acțiuni #7072
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology... Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Preț acțiune
$18.66
Ultima sincronizare: 2026-08-27
Capitalizare de piață
$1.73B
Schimbare (1 zi)
10.41%
Schimbare (1 an)
-54.63%
Țară
CN
Tranzacționează Ascentage Pharma Group International (AAPG)

Categorie

Healthcare
Raport P/E pentru Ascentage Pharma Group International (AAPG)
Raport P/E la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Ascentage Pharma Group International, raportul P/E actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/E de 0.
Istoricul raportului P/E pentru Ascentage Pharma Group International din 2026 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raportul P/E pentru companii similare sau concurenți
Companie P/E Ratio Diferență P/E Ratio Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.